vs

Side-by-side financial comparison of ELBIT SYSTEMS LTD (ESLT) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.

Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $5.8M, roughly 1.6× ELBIT SYSTEMS LTD). ELBIT SYSTEMS LTD runs the higher net margin — 6.3% vs -234.3%, a 240.6% gap on every dollar of revenue.

Elbit Systems Ltd. is an Israel-based international military technology company and defense contractor. Founded in 1966 by Elron, Elbit Systems is the primary provider of the Israeli military's land-based equipment and unmanned aerial vehicles. It is an important company within the defense industry of Israel.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

ESLT vs FHTX — Head-to-Head

Bigger by revenue
FHTX
FHTX
1.6× larger
FHTX
$9.2M
$5.8M
ESLT
Higher net margin
ESLT
ESLT
240.6% more per $
ESLT
6.3%
-234.3%
FHTX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ESLT
ESLT
FHTX
FHTX
Revenue
$5.8M
$9.2M
Net Profit
$367.1K
$-21.7M
Gross Margin
24.3%
Operating Margin
8.3%
-258.2%
Net Margin
6.3%
-234.3%
Revenue YoY
223.8%
Net Profit YoY
-11.1%
EPS (diluted)
$7.85
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESLT
ESLT
FHTX
FHTX
Q4 25
$9.2M
Q3 25
$5.8M
$8.2M
Q2 25
$7.6M
Q1 25
$6.0M
Q4 24
$2.9M
Q3 24
$7.8M
Q2 24
$6.9M
Q1 24
$5.0M
Net Profit
ESLT
ESLT
FHTX
FHTX
Q4 25
$-21.7M
Q3 25
$367.1K
$-15.8M
Q2 25
$-17.9M
Q1 25
$-18.8M
Q4 24
$-19.5M
Q3 24
$-19.1M
Q2 24
$-23.0M
Q1 24
$-25.0M
Gross Margin
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
24.3%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ESLT
ESLT
FHTX
FHTX
Q4 25
-258.2%
Q3 25
8.3%
-226.9%
Q2 25
-279.2%
Q1 25
-385.0%
Q4 24
-840.5%
Q3 24
-305.5%
Q2 24
-386.6%
Q1 24
-558.3%
Net Margin
ESLT
ESLT
FHTX
FHTX
Q4 25
-234.3%
Q3 25
6.3%
-194.4%
Q2 25
-237.3%
Q1 25
-316.4%
Q4 24
-682.9%
Q3 24
-244.9%
Q2 24
-333.6%
Q1 24
-495.4%
EPS (diluted)
ESLT
ESLT
FHTX
FHTX
Q4 25
$-0.35
Q3 25
$7.85
$-0.25
Q2 25
$-0.28
Q1 25
$-0.30
Q4 24
$-0.23
Q3 24
$-0.31
Q2 24
$-0.45
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESLT
ESLT
FHTX
FHTX
Cash + ST InvestmentsLiquidity on hand
$265.4K
$80.9M
Total DebtLower is stronger
$90.7K
Stockholders' EquityBook value
$3.3M
$-108.5M
Total Assets
$11.0M
$198.1M
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESLT
ESLT
FHTX
FHTX
Q4 25
$80.9M
Q3 25
$265.4K
$89.3M
Q2 25
$72.6M
Q1 25
$61.0M
Q4 24
$55.5M
Q3 24
$57.7M
Q2 24
$138.9M
Q1 24
$79.3M
Total Debt
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
$90.7K
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESLT
ESLT
FHTX
FHTX
Q4 25
$-108.5M
Q3 25
$3.3M
$-89.7M
Q2 25
$-76.7M
Q1 25
$-61.7M
Q4 24
$-45.5M
Q3 24
$-28.3M
Q2 24
$-14.3M
Q1 24
$-97.5M
Total Assets
ESLT
ESLT
FHTX
FHTX
Q4 25
$198.1M
Q3 25
$11.0M
$205.0M
Q2 25
$226.2M
Q1 25
$258.7M
Q4 24
$284.0M
Q3 24
$308.4M
Q2 24
$328.6M
Q1 24
$255.0M
Debt / Equity
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
0.03×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESLT
ESLT
FHTX
FHTX
Operating Cash FlowLast quarter
$534.6K
$-22.3M
Free Cash FlowOCF − Capex
$319.6K
FCF MarginFCF / Revenue
5.5%
Capex IntensityCapex / Revenue
3.7%
0.0%
Cash ConversionOCF / Net Profit
1.46×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESLT
ESLT
FHTX
FHTX
Q4 25
$-22.3M
Q3 25
$534.6K
$-18.9M
Q2 25
$-21.0M
Q1 25
$-24.0M
Q4 24
$-24.5M
Q3 24
$-21.0M
Q2 24
$-25.5M
Q1 24
$-29.3M
Free Cash Flow
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
$319.6K
Q2 25
$-21.0M
Q1 25
$-24.0M
Q4 24
$-25.0M
Q3 24
$-21.3M
Q2 24
$-25.6M
Q1 24
$-29.4M
FCF Margin
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
5.5%
Q2 25
-278.2%
Q1 25
-403.2%
Q4 24
-875.3%
Q3 24
-273.0%
Q2 24
-371.0%
Q1 24
-583.1%
Capex Intensity
ESLT
ESLT
FHTX
FHTX
Q4 25
0.0%
Q3 25
3.7%
0.0%
Q2 25
0.3%
Q1 25
0.5%
Q4 24
16.8%
Q3 24
4.0%
Q2 24
0.2%
Q1 24
2.0%
Cash Conversion
ESLT
ESLT
FHTX
FHTX
Q4 25
Q3 25
1.46×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons